Qualigen Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QLGN research report →
Price Chart
About the company
Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing groundbreaking treatments for both cancer and infectious diseases. In addition to its developmental pipeline, the company offers FastPack, an efficient system designed for swift diagnostic testing.
- CEO
- Kevin A. Richardson II
- IPO
- 2015
- Employees
- 4
- HQ
- Carlsbad, CA, US
Get TickerSpark's AI analysis on QLGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.43M
- P/E
- -0.08
- PEG
- -0.00
- P/S
- 2077.99
- P/B
- 1.73
- EV/EBITDA
- -0.25
- Div Yield
- 0.00%
- Gross Margin
- -215.54%
- Op Margin
- -424087.01%
- Net Margin
- -527369.17%
- ROE
- -156.03%
- ROIC
- -381.57%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-13,202,096
- Net Income
- $-19,528,742-217.1%
- EPS
- $-8.11+53.1%
- OCF Growth
- -9.9%
- FCF Growth
- -9.9%
- 52W High
- $8.81
- 52W Low
- $1.61
- 50D MA
- $3.63
- 200D MA
- $3.20
- Beta
- 0.28
- RSI (14)
- 46
- Avg Volume
- 2.65M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
FF Robotics said third-quarter reported results were pre-acquisition, while the acquired robotics business showed accelerating revenue, and management reaffirmed a 2026 target of about 2,000 robots sold and shipped with positive unit gross margins.· November 12, 2026
- Third-quarter consolidated results did not include the robotics business because the acquisition closed on October 23; the call focused on the acquired business’s pre-closing performance and post-close strategy.
- The acquired robotics business generated about $2.3 million of revenue in the first 9 months of 2026, including about $1.1 million in Q3 alone, with gross margin of about 26%.
- October device sales and shipments reached a record 351 units, bringing cumulative sales and shipments to 1,168 units.
- Management reaffirmed full-year 2026 guidance of about 2,000 robots sold and shipped with positive unit gross margins on a stand-alone basis.
- The company emphasized new products and platforms, including Nova, Nova Mini, OmniMind, developer tools, and expansion of RoboShare and Built in U.S.A. plans.
FFR’s reported third-quarter 2026 consolidated results excluded the acquired robotics business because the acquisition closed after quarter-end. On a pre-acquisition basis, the robotics business generated approximately $2.3 million of revenue in the first 9 months of 2026, including approximately $1.1 million in Q3; gross profit was approximately $593,000 and gross margin was approximately 26%; operating expenses were approximately $28 million; and net loss was approximately $27.4 million. Management also said October sales and shipments hit 351 devices, bringing cumulative sales and shipments to 1,168 units, and reaffirmed full-year 2026 guidance of approximately 2,000 robots sold and shipped with positive unit gross margins. For FFR’s reported quarter, management said the company ended Q3 with $3.2 million in cash and cash equivalents, $6.9 million in total assets, and net loss of approximately $2.7 million; in a later Q&A answer they also cited $5 million of stockholders’ equity as of September 30, 2026. Management said the company will need to raise additional capital to fund operations, and that the acquisition was completed entirely in stock with no cash proceeds.
YT Jia said the company has now shifted into a pure-play robotics business built around a full-stack AI ecosystem spanning humanoid, quadruped, and mobile manipulator robots. His tone was focused on execution and commercialization: launching new products, expanding the developer platform, scaling education and industry use cases, and turning data collected in the field into better models and products. He also emphasized that resources formerly tied to digital assets have been redeployed to robotics and that governance and SEC reporting processes are being strengthened for the Nasdaq-listed operating company.
Jerry Wang highlighted the financial profile of the acquired robotics business before closing: about $2.3 million of revenue over 9 months, about $593,000 of gross profit, about 26% gross margin, about $28 million of operating expenses, and about $27.4 million of net loss. He noted that roughly $24.4 million of costs were funded directly by the parent as capital contributions and that cash used in operating activities was about $2.5 million, calling the structure relatively lean. He also pointed to a clean balance sheet at closing with about $4.9 million of cash and cash equivalents, $8.2 million of total assets, $1.4 million of liabilities, and no outstanding borrowings or convertible debt, while warning that FFR still has substantial doubt about going concern and will need additional capital.
Analysts asked how confident management is in the 2026 guidance and near-term growth; management reaffirmed about 2,000 robots sold and shipped with positive unit gross margins and cited the year-to-date ramp, including 351 units in October, while saying the next few quarters are the near-term focus. Questions also focused on the balance sheet, and management clarified that the Q3 reported numbers exclude the acquired robotics business, that the acquisition was stock-only, and that additional capital will be needed. Other questions covered sales channels, geography, and regulation: management described traction in education, security and inspection, and commercial services, and said U.S. rules on foreign-made robotics could affect where and when projects can be deployed and at what cost.
The main bullish signal was the apparent commercialization ramp: the robotics business nearly matched first-half revenue in Q3 alone, and October shipments hit a record 351 devices. Management also said the business has launched more than 20 products across three form factors, has active data orders, and is seeing early customer validation in education, security and inspection, and commercial services. The company is also pushing new products and platforms, including Nova, Nova Mini, OmniMind, RoboShare, and a U.S. manufacturing plan.
The call also highlighted meaningful financial and execution risks: FFR said there is substantial doubt about its ability to continue as a going concern and that it will need additional capital. The acquired robotics business is still loss-making, with about $27.4 million of net loss over 9 months versus about $2.3 million of revenue, and management said some initiatives remain in proof-of-concept or technical feasibility stages. Regulatory uncertainty around foreign-made robotics hardware and software could affect deployment timing, cost, and project eligibility.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 100.2%
- Shares Outstanding
- 1.69M
- Float Shares
- 1.70M
of shares held by institutions
25 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Qs Investors, LLC | 82.00K | 0 |
| Hatton Consulting, Inc. | 27.20K | ▼ 10.00K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 7, 24 | Bensler Graydon | other | 0 |
| Oct 8, 24 | Braeden Lichti | other | 0 |
| Jul 12, 24 | LIM ROBERT BRADLEY | other | 0 |
| Jul 12, 24 | BECHER CAMPBELL | other | 0 |
| Jul 12, 24 | PRICE CODY | other | 0 |
| Jul 11, 22 | Abdul-Ahad Wajdi | other | 80,000 |
| Jul 11, 22 | Lotz Christopher L. | other | 100,000 |
| Jul 11, 22 | Lotz Christopher L. | other | 100,000 |
| Jul 11, 22 | ARSHAD TARIQ | other | 102,000 |
| Jul 11, 22 | Ritter Ira E. | other | 40,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our QLGN coverage
Recent articles, reports, and earnings notes.
No research on QLGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate QLGN report →Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy
globenewswire.com · Nov 16
Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025
globenewswire.com · Oct 27
Biotech Stocks To Add to Your Watchlist – October 24th
defenseworld.net · Oct 26
Qualigen Therapeutics (QLGN) Stock Soars 62% After-Hours On Partnership With BitGo To Build Multi-Asset Crypto Treasury
benzinga.com · Oct 24
Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation
globenewswire.com · Oct 23
Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?
globenewswire.com · Oct 12
Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition
globenewswire.com · Oct 6
Univest Securities, LLC Announces Closing of $41 Million Strategic Investment in Client Qualigen Therapeutics (NASDAQ: QLGN) from Client Faraday Future (NASDAQ: FFAI)
globenewswire.com · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.